BISPECTRA

100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	25-Jun-2020	25-Jun-2023	: Date of Next Review
Prepared By:	Amy Hosein	Not Applicable	: Supersedes
QA/QC Approval:	Carissa McCollian	Wendy Santay	: Management Approval
Reason for Revision:	See Revision History in ensur.		

CERTIFICATE OF ANALYSIS POTASSIUM BROMIDE BIO ACTIVE GRADE / PB2220-G500 LOT#: PB2220-007-0620

KBr * F.W. 119.00 g mol * CAS#: 7758-02-3 Manufacturing Date: 6/10/20 Retest Date: 6/30/22 Manufacturing Site: 100 Majestic Way, Bangor PA, 18013 Packaging Date: 6/12/20 Packaging Site: 100 Majestic Way, Bangor PA, 18013 Meets or exceeds USP Specifications

TEST		Specification	TEST RESULT	
Acidity or Alkalinity		Passes Test	Passes Test	
Appearance of Solution		Clear and Colorless	Clear and Colorless	
Assay		98.0 - 100.5%	100.4%	
Bromates		Passes Test	Passes Test	
Heavy Metals		10 ppm max.	< 10 ppm	
T1 ('C' ('	А	Passes Test	Passes Test	
Identification	В	Passes Test	Passes Test	
Iodides		Passes Test	Passes Test	
Limit of Chlorine		0.6% max.	<0.6%	
Limit of Iron		20 ppm max.	< 20 ppm	
Loss on Drying		1.0% max.	0.2%	
Magnesium and Alkaline Earth-Metals		0.02% max.	<0.02%	
Sulfates		0.01% max.	<0.01%	
	Arsenic (As)	5 ppm max.	< 5 ppm	
	Copper (Cu)	5 ppm max.	< 5 ppm	
Trace Metals	Iron (Fe)	5 ppm max.	< 5 ppm	
	Lead (Pb)	5 ppm max.	< 5 ppm	

COUNTRY OF ORIGIN: U.S.A.

TEST METHOD REFERENCE: DCN: 16-001310

An original approved version of this document includes colored text. The information contained herein is the property of BioSpectra. The recipient is responsible for its safe-keeping, and the prevention of unauthorized appropriation, use, disclosure and copying.

CAUTION STATEMENT: For use in development only not for commercial distribution.

CAUTION STATEMENT: Rx only.

<u>INTENDED USE:</u> Material represented by this Certificate of Analysis is suitable for use as a non-Sterile Active Pharmaceutical Ingredient manufactured in accordance with the ICH Q7 Good Manufacturing Practice Guide. The material represented by this Certificate of Analysis is not suitable to be used as a Sterile or Injectable Active Pharmaceutical Ingredient, Drug Product or Household Item.

STATEMENT: Meets the chemical testing specifications of the current edition of the European Pharmacopoeia.

<u>OVI STATEMENT</u>: Based on the manufacturing process and the controlled handling, storage and analysis of this product, this product complies with the requirements and specifications listed in the current USP method <467> Tables 1, 2, 3, or 4.

Prepared by:	Date: _	6/29/20	Job Title:	ASupervisor
Reviewed by:	Date:	(0/29/20	Job Title: <u>()</u>	Minger